目前还有哪些低估值板块值得布局？

Group 1: Consumer Sector - The consumer sector is currently undervalued, with the China Securities Consumer Index's price-to-earnings (P/E) ratio around 20 times, placing it in the 14th percentile historically over the past five years, indicating a very low valuation [4] - The low valuation in the consumer sector is primarily driven by the high weight of liquor stocks, which has negatively impacted overall valuations [5] - Excluding liquor, the optional consumer sector has a valuation of approximately 19 times, which is around the 40th percentile historically over the past decade, also indicating a low valuation [6] - The consumer sector presents a good investment opportunity due to its attractive price-performance ratio, especially for those looking to avoid high-flying sectors [7] - There has been significant interest in consumer investments, with consumer ETFs seeing a rapid increase in shares, adding over 15 billion in the last six months and net inflows exceeding 10 billion [8] - Current policies are promoting consumption, making it a favorable time for investment in the consumer sector [10] Group 2: Pharmaceutical Sector - The pharmaceutical sector has been largely absent from the recent bull market, with the China Securities Pharmaceutical Index only increasing by 25% since September 2024, significantly lagging behind the broader market [12][13] - The valuation in the pharmaceutical sector is very low, with a price-to-book (P/B) ratio of around 3 times, placing it in the 20th percentile historically over the past decade [14] - The current valuation levels in the pharmaceutical sector are comparable to the lows seen during the bear market in 2018, indicating a severe absence from the recent bull market [15] - Within the pharmaceutical sector, medical devices and traditional Chinese medicine are notable sub-sectors, with medical devices having an even lower valuation, with a P/B ratio around 3 times, marking it as one of the cheapest periods historically [16] - The medical device sector has several positive narratives, including international expansion, domestic substitution, and product innovation, supported by government incentives for hospitals to upgrade equipment, which could improve industry performance [17] - Despite the potential, short-term upward movement in medical devices may be challenging, requiring catalysts or actual performance improvements to drive growth [19]